66 related articles for article (PubMed ID: 2189474)
21. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
[TBL] [Abstract][Full Text] [Related]
22. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
23. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
24. The role of chemotherapy in diffuse aggressive lymphomas.
DeVita VT; Hubbard SM; Young RC; Longo DL
Semin Hematol; 1988 Apr; 25(2 Suppl 2):2-10. PubMed ID: 3041598
[TBL] [Abstract][Full Text] [Related]
25. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Kröger N; Hoffknecht M; Hänel M; Krüger W; Zeller W; Stockschläder M; de Wit M; Weh HJ; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
[TBL] [Abstract][Full Text] [Related]
26. [Progress in therapeutic strategy for malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
[TBL] [Abstract][Full Text] [Related]
27. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
28. The present status of therapy for patients with aggressive non-Hodgkin's lymphoma.
Vose JM; Armitage JO
Ann Oncol; 1991 Feb; 2 Suppl 2():171-6. PubMed ID: 2049315
[TBL] [Abstract][Full Text] [Related]
29. Management of the patient with large cell lymphoma.
Levine AM
Blood Rev; 1988 Jun; 2(2):71-7. PubMed ID: 3042059
[TBL] [Abstract][Full Text] [Related]
30. Low-grade lymphomas: new entities and treatment concepts.
Hagemeister FB
Med Oncol; 1995 Sep; 12(3):131-42. PubMed ID: 8852395
[TBL] [Abstract][Full Text] [Related]
31. Renal Lymphoma: Primary or First Manifestation of Aggressive Pediatric B-cell Lymphoma.
Coca P; Linga VG; Gundeti S; Tandon A
Indian J Med Paediatr Oncol; 2017; 38(4):538-541. PubMed ID: 29333026
[TBL] [Abstract][Full Text] [Related]
32. Nuances in the Management of Aggressive Lymphomas.
Hamlin PA; Wisniewski M
J Adv Pract Oncol; 2017 Apr; 8(3):279-284. PubMed ID: 29928552
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapeutic management of lymphomas; effect upon survival.
SHIMKIN MB
Harlem Hosp Bull; 1955 Sep; 8(2):62-78. PubMed ID: 13241894
[No Abstract] [Full Text] [Related]
34. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis.
Greenstein RJ; Su L; Haroutunian V; Shahidi A; Brown ST
PLoS One; 2007 Jan; 2(1):e161. PubMed ID: 17252054
[TBL] [Abstract][Full Text] [Related]
35. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas.
Mochen C; Giardini R; Costa A; Silvestrini R
Cell Prolif; 1997 Jan; 30(1):37-47. PubMed ID: 9332493
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?
Child JA
Br J Cancer; 1991 Jun; 63(6):837-40. PubMed ID: 2069841
[No Abstract] [Full Text] [Related]
38. Contribution of 3H-thymidine labelling index and flow cytometric S-phase in predicting survival of patients with non-Hodgkin's lymphoma.
Costa A; Silvestrini R; Giardini R; Messina-Gabrielli G; Boracchi P; Veneroni S
Br J Cancer; 1992 Oct; 66(4):680-4. PubMed ID: 1419606
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients with aggressive lymphomas: an overview.
Urba WJ; Duffey PL; Longo DL
J Natl Cancer Inst Monogr; 1990; (10):29-37. PubMed ID: 2189474
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
